Together, these results provide a rationale for targeting EGF-like factors (HB-EGF, AREG and TGF-α) and proteases (MMP1 and ADAMTS1) in tumour cells, as well as EGFR in osteoblasts for controlling osteolytic bone metastasis of breast cancer. Here, EGFR is linked to neoplasm.